文献速递贫血与红细胞疾病

口服精氨酸治疗尼日利亚镰状细胞贫血疼痛住院儿童的随机对照试验

Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria.
PubMed 文献 · Am J Hematol · 2020-11-20

结果显示精氨酸组总镇痛药物用量显著低于安慰剂组,疼痛缓解更快,危象缓解时间和住院时间更短,且无严重不良事件。

要点

  • 口服精氨酸显著降低镰状细胞贫血疼痛危象患儿的镇痛药物总用量。
  • 精氨酸组疼痛评分下降更快,危象缓解时间和住院时间更短。
  • 口服精氨酸安全性良好,无严重不良事件,可作为有前景的辅助治疗。

核心结论

  • 口服精氨酸可减少镰状细胞贫血疼痛危象住院患儿的镇痛需求,加快疼痛控制和危象缓解,缩短住院时间。

研究设计与样本

  • 患儿随机接受口服L-精氨酸盐酸盐(100 mg/kg 每日三次,35例)或安慰剂(33例),采用意向性分析。

主要发现

  • 精氨酸组平均总镇痛药物量化评分(MQS)为73.4(95% CI 62.4-84.3),安慰剂组为120.0(95% CI 96.7-143.3),P < .001。
  • 精氨酸组最严重疼痛评分下降速率快于安慰剂组(1.50 [95% CI 1.23-1.77] vs 1.09 [95% CI 0.94-1.24] 分/天,P = .009)。
  • 精氨酸组危象缓解时间更短(P = .02),住院时间更短(P = .002),且无严重不良事件。

临床怎么用

  • 对于镰状细胞贫血血管闭塞性疼痛危象住院患儿,口服精氨酸可作为辅助治疗以减少镇痛药物用量并加快恢复。
  • 口服精氨酸安全性良好且成本低,在资源有限地区具有应用前景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low arginine bioavailability is associated with vaso-occlusive painful crisis (VOC) severity in sickle cell anemia (SCA) and predicts need for pediatric hospitalization. Intravenous arginine therapy has opioid-sparing effects and was found to significantly decrease pain scores in children hospitalized with SCA-VOC in a phase-two randomized placebo-controlled trial (RCT). Efficacy of oral arginine is unknown. Our objective was to determine the safety and efficacy of oral arginine therapy in Nigerian children with SCA. A double-blind RCT of oral L-arginine-hydrochloride (100 mg/kg TID) was conducted in children with SCA-VOC, aged 5-17 years, hospitalized at two Nigerian sites. The primary outcome measure was analgesic usage, quantified by difference in the mean Analgesic Medication Quantification Scale (MQS). Secondary outcomes included daily pain scores, time-to-crisis-resolution and length-of-hospital-stay. An intention-to-treat analysis was performed. Sixty-eight children (age 5-17 years, mean 10.6 ± 0.4 years; 56% male), were randomized to receive L-arginine (35 patients) or placebo (33 patients). The mean total MQS for the arginine group was 73.4 (95% CI, 62.4-84.3) vs 120.0 (96.7-143.3) for placebo (P < .001). The mean rate of decline in worst pain scores was faster in the arginine arm vs placebo (1.50 [1.23-1.77] vs 1.09 [0.94-1.24] point/d, P = .009). Children receiving arginine had a shorter time-to-crisis-resolution (P = .02), shorter hospital-stay (P = .002) and experienced no serious adverse event. Pain control was more rapid, total analgesic requirement was significantly reduced, and most notably, time-to-crisis-resolution and length-of-hospital-stay were shorter in children with SCA-VOC receiving arginine vs placebo. Given the established safety and low cost, oral arginine is a promising adjuvant therapy for SCA-VOC management.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Onalo R, Cooper P, Cilliers A, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol. 2020. PMID: 33075179. doi:10.1002/ajh.26028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。